Imaging Diagnosis of Primary Liver Cancer Using Magnetic Resonance Dilated Weighted Imaging and the Treatment Effect of Sorafenib

Table 1

Evaluation criteria of RECIST1.1.

Efficacy classification	Symptom descriptions
Progressive disease (PD)	The largest diameter and the lowest increase of the target lesion was ≥20% or the new lesion was found
Stable disease (SD)	The largest diameter and decrease in diameter of the target lesion did not reach PR or the enlargement diameter did not reach PD
Partial response (PR)	The largest diameter and decrease in diameter of the target lesion reached ≥30% and maintained for more than 4 weeks
Complete response (CR)	All target lesions disappeared, no new lesions appeared, and the tumor markers were normal and maintained for more than 4 weeks

Note: PR+CR was ORR; total DCR was the value of SD+PR+CR.